Abstract 71P
Background
It has been proposed that around 3.5% of all human genes are directly linked to the onset of cancer. These cancer driver genes accumulate mutations, ultimately leading to tumorigenesis. Despite the known importance of cancer driver genes, their interactions in tissue-specific environments remain poorly understood. One approach to address this gap is to study the protein physical interactions (PPI) between drivers and their neighbors. We propose that when a driver mutation occurs, the PPIs with neighbor proteins can impact the mutation tumorigenic effect.
Methods
To test our hypothesis, we looked at patient mutations and gene expression data from the Cancer Genome Atlas Pan-Cancer Cohort. Cancer driver genes were retrieved from NCG and PPIs were obtained from multiple databases. Statistical analyses were used to detect neighbors whose expression is associated with driver mutation status. We also analyzed the difference in neighbor expression between tumor and the matching non-tumoral tissue; when no difference was detected we excluded that the mutation was influencing the neighbor gene expression.
Results
We identified more than 3000 neighbors significantly associated with at least one driver, within different cancer types and within individuals within the same type of cancer. Around 65% of driver genes analyzed had significant neighbors. Interestingly, most neighbors had coherent associations with multiple interacting drivers, either strictly promoting or strictly inhibiting driver mutation tumorigenic effects. We hypothesized that these neighbors could have a detectable influence in cancer development across multiple cancer types. Selecting the top 50 most frequent significant neighbors with coherent associations, Kaplan-Meier analysis showed a significant impact on patient overall survival.
Conclusions
This study supports that driver PPIs can influence cancer development. Pharmacologically changing the abundance of these neighbor proteins (or the stability of their PPIs) may help to alleviate driver mutation effects. The identification of these neighbor proteins implicated in tumorigenesis is an opportunity to advance both personalized treatment of cancer and provide new targets for drug development.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
UIDB/04046/2020 (DOI: 10.54499/UIDB/04046/2020 ) and UIDP/04046/2020 (DOI: 10.54499/UIDP/04046/2020) Centre grants from FCT, Portugal (to BioISI).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Numb serves as a prognostic biomarker and promotes lung adenocarcinoma brain metastasis
Presenter: Yanyan Zhao
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Integrin-fibronectin interplay is a pivotal biological and clinical determinant in papillary thyroid carcinoma
Presenter: Domenico Rocco
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Correlation of IL-6 and c-reactive protein levels with the stage, differentiation and types of colorectal cancer
Presenter: MOHAMED MAHBOOB ALI
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis
Presenter: José Leão Mendes
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Assessment of cancer testis antigen 45 for diagnostic and prognostic applications in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Integrative omics workflow identifies credible druggable targets in high-grade serous cancer
Presenter: Taru Muranen
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - Impact of IHC/PCR discordance on immunotherapy (ICI) response in colorectal cancer (CRC) patients and prospects of liquid biopsy (LB) to replace conventional methods: Survival analysis of BLOOMSI trial
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Response of gastric adenocarcinoma to neoadjuvant chemotherapy with respect to the presence or absence of HER2 overexpression: A prospective observational study
Presenter: Pratap Deb
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine
Presenter: Preeti Paliwal
Session: Cocktail & Poster Display session
Resources:
Abstract